Ownership and insider activity for Aptorum Group Limited (APM): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.
Price
| Price | $8.26 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.2M | $12.0M | $5.2M | $3.5M | $8.1M | $1.9M | $2.0M | $874238 | $3.5M |
| Short-term Investments | $2.0M | $1.0M | $1.1M | $28.4M | $236615 | $102481 | 0 | 0 | 0 |
| Receivables | $179492 | $990846 | $487590 | $341063 | $3.6M | $1.2M | $70945 | $4545 | 0 |
| Inventory | $1.5M | $30642 | $34185 | $39133 | $35775 | $27722 | 0 | 0 | 0 |
| Total Current Assets | $20.3M | $28.7M | $8.0M | $33.7M | $12.7M | $7.1M | $2.5M | $959554 | $3.6M |
| Property, Plant & Equipment | $346587 | $4.3M | $7.1M | $5.4M | $4.0M | $3.2M | $1.8M | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $1.5M | $1.4M | $1.3M | $964857 | $880256 | $752705 | $147347 | 0 | 0 |
| Total Assets | $31.6M | $45.1M | $24.0M | $44.2M | $21.9M | $20.9M | $20.6M | $16.1M | $18.7M |
| Accounts Payable | 0 | $40139 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | $480000 | $10.1M | 0 | $627922 | 0 | $6.0M | 0 | $3.2M | $3.4M |
| Total Current Liabilities | $1.3M | $12.2M | $2.7M | $3.9M | $4.4M | $12.5M | $2.1M | $4.3M | $4.6M |
| Long-term Debt | 0 | 0 | $6.3M | $2.0M | 0 | $500000 | $3.1M | 0 | 0 |
| Total Liabilities | $1.3M | $12.3M | $9.1M | $6.1M | $4.4M | $13.0M | $5.3M | $4.4M | $4.9M |
| Retained Earnings | -$2.5M | -$17.4M | -$37.6M | -$30.5M | -$55.5M | -$65.3M | -$68.2M | -$72.4M | -$73.8M |
| Total Equity | $30.2M | $33.1M | $16.4M | $41.8M | $23.6M | $15.7M | $24.8M | $21.1M | $23.1M |
| Total Debt | $480000 | $10.3M | $6.5M | $3.3M | $217167 | $6.9M | $3.3M | $3.4M | $3.4M |
| Net Debt | -$17.7M | -$2.7M | $222232 | -$28.6M | -$8.2M | $4.9M | $1.3M | $2.5M | -$9963 |
| Working Capital | $19.0M | $16.5M | $5.4M | $29.8M | $8.3M | -$5.4M | $377339 | -$3.4M | -$1.0M |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 0.78 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.96 |
Profitability
| Return on Equity | -5.90% |
| Return on Invested Capital | -10.36% |
| Return on Assets | -7.29% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADIL · ADXN · ARDS · ATHE · ATXI · OXBR · RKTO
Explore sector: Healthcare · Biotechnology
More sections of APM: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks